Even though prostate cancer is the second leading cause of cancer related mortality in men in the United States, there is an ongoing concern that as a medical community we are over diagnosing, and hence over treating, the disease. Yet, patients at high-risk for metastatic progression are unfortunately treated too late. We hypothesized that tissue chemokines can be strong biomarker candidates for distinguishing patients with high risk for biochemical recurrence ...
Reports by Author
